血浆末端补体复合物评估的补体激活与静脉血栓栓塞未来风险
在Tromsø人群队列的巢式病例对照研究中,纳入415例静脉血栓栓塞(VTE)病例和848例年龄性别匹配对照,发现血浆末端补体复合物(TCC)水平最高四分位组与最低四分位组相比,无诱因VTE的OR为1.74(95%CI 1.10-2.78),未发现基因变异与TCC水平相关。
要点
- 血浆TCC最高四分位(>1.40任意单位/mL)者无诱因VTE风险升高,OR 1.74(95%CI 1.10-2.78)。
- VTE事件前短期采集的样本中观察到VTE风险更高。
- 全基因组及补体相关基因变异与血浆TCC水平无关联。
核心结论
- 高水平的血浆TCC与VTE风险相关,尤其是无诱因事件。
- 基因变异与血浆TCC水平之间无全基因组关联。
研究设计与样本
- 巢式病例对照研究,样本来自基于人群的Tromsø研究队列。
- 纳入415例VTE病例和848例年龄、性别匹配的对照。
- 采用逻辑回归计算血浆TCC四分位组间VTE的比值比及95%置信区间。
- 使用Agilent SureSelect 50 Mb捕获试剂盒进行全外显子测序,并利用蛋白数量性状位点分析探索与TCC相关的遗传变异。
主要发现
- 随着血浆TCC四分位升高,VTE风险增加,尤其对于无诱因VTE。
- 在调整年龄、性别和体重指数后,TCC最高四分位(>1.40补体任意单位/mL)者与最低四分位(≤0.80补体任意单位/mL)者相比,无诱因VTE的OR为1.74(95%CI 1.10-2.78)。
- 在VTE事件前不久采集的样本中观察到VTE风险显著更高。
- 未发现全基因组或补体相关基因变异与血浆TCC水平之间存在关联。
关键数值与推荐
- TCC最高四分位定义为>1.40补体任意单位/mL,最低四分位定义为≤0.80补体任意单位/mL。
- 无诱因VTE的OR为1.74(95%CI 1.10-2.78),比较最高四分位组与最低四分位组,调整年龄、性别和体重指数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It remains uncertain whether activation of the complement system, assessed by the soluble terminal C5b-9 complement complex (plasma TCC), is associated with future risk of incident venous thromboembolism (VTE). OBJECTIVES: To investigate the association between plasma levels of TCC and future risk of incident VTE in a nested case-control study, and to explore genetic variants associated with TCC using protein quantitative trait loci analysis of exome sequencing data. METHODS: We sampled 415 VTE cases and 848 age- and sex-matched controls from a population-based cohort, the Tromsø study. Logistic regression models were used to calculate odds ratios with 95% confidence intervals for VTE across quartiles of plasma levels of TCC. Whole exome sequencing was conducted using the Agilent SureSelect 50 Mb capture kit. RESULTS: The risk of VTE increased across increasing quartiles of plasma TCC, particularly for unprovoked VTE. Participants with TCC in the highest quartile (>1.40 complement arbitrary units/mL) had an odds ratio for unprovoked VTE of 1.74 (95% confidence interval: 1.10-2.78) compared with those with TCC in the lowest quartile (≤0.80 complement arbitrary units/mL) in analyses adjusted for age, sex, and body mass index. A substantially higher risk for VTE was observed in samples taken shortly before VTE event. We found no association between genome-wide or complement-related gene variants and plasma levels of TCC. CONCLUSIONS: We found that high levels of plasma TCC were associated with VTE risk, and unprovoked events in particular. There was no genome-wide association between gene variants and plasma levels of TCC.
引用
- Høiland II, Liang RA, Braekkan SK, et al. Complement activation assessed by the plasma terminal complement complex and future risk of venous thromboembolism. J Thromb Haemost. 2019. PMID: 30920726. doi:10.1111/jth.14438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。